EAM
PCVX icon

Eventide Asset Management’s Vaxcyte PCVX Stock Holding History

Eventide Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2M Buy
1,380,219
+5,927
+0.4% +$322K 1.07% 22
2026
Q1 		$79.8M Buy
1,374,292
+457,177
+50% +$24.8M 1.32% 15
2025
Q4 		$42.3M Buy
917,115
+537,785
+142% +$24.1M 0.66% 53
2025
Q3 		$13.7M Sell
379,330
-468,811
-55% -$15.5M 0.22% 116
2025
Q2 		$27.6M Buy
848,141
+377,911
+80% +$12.4M 0.48% 76
2025
Q1 		$17.8M Buy
470,230
+86,776
+23% +$6.94M 0.35% 92
2024
Q4 		$31.4M Hold
383,454
– – 0.57% 58
2024
Q3 		$43.8M Sell
383,454
-355,699
-48% -$32.1M 0.76% 45
2024
Q2 		$55.8M Buy
739,153
+81,947
+12% +$5.58M 0.96% 33
2024
Q1 		$44.9M Buy
657,206
+50,000
+8% +$3.46M 0.7% 53
2023
Q4 		$38.1M Buy
607,206
+214,206
+55% +$11.1M 0.62% 55
2023
Q3 		$20M Buy
+393,000
New +$19.4M 0.36% 83

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Eventide Asset Management's PCVX Position: Q2 2026 in Review

Eventide Asset Management increased its Vaxcyte (PCVX) stake by 0.43% in Q2 2026, buying an estimated $322K and bringing the position to 1,380,219 shares worth $80.2M. The position accounts for 1.07% of the portfolio, ranked #22.

Eventide Asset Management first reported a position in PCVX in Q3 2023 and has held it in 12 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Eventide Asset Management held 1,380,219 shares of Vaxcyte worth $80.2M as of Q2 2026.
  • Eventide Asset Management bought 5,927 Vaxcyte shares in Q2 2026, an estimated $322K.
  • Vaxcyte made up 1.07% of Eventide Asset Management's portfolio in Q2 2026, its #22 holding.
  • Eventide Asset Management first reported a position in Vaxcyte in Q3 2023 and has held it in 12 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.